FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress

Erdafitinib, an oral pan-FGFR inhibitor, demonstrated encouraging clinical activity and a manageable safety profile in Asian patients with FGFR-aberrant advanced cholangiocarcinoma.

The potent FGFR1-3 inhibitor pemigatinib showed preliminary efficacy and safety signals in the phase II FIGHT-202 trial (NCT02924376) of patients with previously treated advanced, metastatic or surgically unresectable cholangiocarcinoma.

Sameek Roychowdhury, MD, PhD, discusses the potential for FGFR inhibitors in the treatment of patients with cholangiocarcinoma who harbor FGFR fusions.

The selective pan-FGFR kinase inhibitor infigratinib showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma who harbor FGFR2 fusions.